Using cancer vaccines or adoptively transferred T cells, we demonstrate here that the tumor-killing efficacy of CD8 T cells against established melanoma and glioblastoma tumors can be greatly enhanced by modulating the TME with a potent synthetic TLR4 agonist. The gene discussed is CD8A; the disease is neoplasm.